{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:42:56Z","timestamp":1787161376885,"version":"build-2736575974"},"reference-count":45,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The World Anti\u2010Doping Agency (WADA) has recently implemented dried blood spots (DBSs) as a matrix for doping control. However, specifications regarding the analysis of the class of prohibited substances called erythropoietin (EPO) receptor agonists (ERAs) from DBSs are not yet described. The aim of this study was to find optimal conditions (sample volume and storage) to sensitively detect endogenous erythropoietin (hEPO) and prohibited ERAs from DBSs and compare detection limits to WADA\u2010stipulated minimum required performance levels (MRPLs) for ERAs in serum\/plasma samples. Venous whole blood was spotted onto Whatman 903 DBS cards with primarily 60\u2009\u03bcl of blood, but various volumes from 20 to75 \u03bcl were tested. All samples were immunopurified with MAIIA EPO Purification Gel kit (EPGK) and analysed with sodium\n                    <jats:italic>N<\/jats:italic>\n                    \u2010lauroylsarcosinate polyacrylamide gel electrophoresis (SAR\u2010PAGE) and Western blot. Sixty\u2010microliter DBSs allowed the detection of the four main ERAs (BRP, NESP, CERA and EPO\u2010Fc) at concentrations close to WADA's MRPLs described for 500\u2009\u03bcl of serum\/plasma. Different storage temperatures, from \u221220\u00b0C to 37\u00b0C, were evaluated and did not affect ERA detection. A comparison of the detection of endogenous EPO from the different anti\u2010doping matrices (urine, serum and DBSs produced from upper arm capillary blood) from five participants for 6\u2009weeks was performed. Endogenous EPO extracted from DBSs showed intra\u2010individual variations in male and female subjects, but less than in urine. Doping controls would benefit from the stability of ERAs on DBSs: It can be a complementary matrix for ERA analysis, particularly in the absence of EPO signals in urine.\n                  <\/jats:p>","DOI":"10.1002\/dta.3260","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T20:08:18Z","timestamp":1648066098000},"page":"1377-1386","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti\u2010doping application"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-7364","authenticated-orcid":false,"given":"Carmel E.","family":"Heiland","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Clinical Pharmacology, Karolinska University Laboratory Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ericsson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Laboratoire AntiDopage Fran\u00e7ais (LADF) University of Paris\u2010Saclay  Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pohanka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Clinical Pharmacology, Karolinska University Laboratory Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1053-2345","authenticated-orcid":false,"given":"Lena","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Karolinska Institute  Stockholm Sweden"},{"name":"Clinical Pharmacology, Karolinska University Laboratory Karolinska University Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-6939","authenticated-orcid":false,"given":"Alexandre","family":"Marchand","sequence":"additional","affiliation":[{"name":"Laboratoire AntiDopage Fran\u00e7ais (LADF) University of Paris\u2010Saclay  Ch\u00e2tenay\u2010Malabry France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1992.72.2.449"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.43.649"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.933.367"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1387\u20102656(08)70055\u20103"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455387"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986709787846668"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019030266"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.suppl_3.3"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1381"},{"key":"e_1_2_8_11_1","unstructured":"WADA.World anti\u2010doping code. Prohibited list2022.https:\/\/www.wada-ama.org\/en"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.32.3.338"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010012\u20106626\u2010y"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1803"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010012\u20106043\u20102"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2418"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2872"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010011\u20105655\u20102"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102018\u20100313"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.311902"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2016.12.008"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.04.008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010020\u201002634\u20104"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/46.4.515"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.342"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.03.013"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.7b02492"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2185"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1579"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2004"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/sms.12049"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3135"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.03.055"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3142"},{"key":"e_1_2_8_35_1","unstructured":"WADA.Harmonization of analysis and reporting of erythropoietin (EPO) and other EPO\u2010receptor agonists (ERAs) by polyacrylamide gel electrophoretic (PAGE) analytical methods. TD2022EPO.https:\/\/www.wada-ama.org\/en"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2730"},{"key":"e_1_2_8_37_1","unstructured":"WADA.2020Anti\u2010doping Testing Figures.https:\/\/www.wada-ama.org\/en"},{"key":"e_1_2_8_38_1","unstructured":"WADA.Dried blood spots (DBS) for doping control. TD2021DBS.https:\/\/www.wada-ama.org\/en"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003\u20102697(02)00407\u20104"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102007\u2010965159"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2601"},{"key":"e_1_2_8_42_1","first-page":"1","article-title":"Data from a microdosed recombinant human erythropoietin administration study applying the new biotinylated clone AE7A5 antibody and a further optimized sarcosyl polyacrylamide gel electrophoresis protocol","author":"Reichel C","year":"2021","journal-title":"Drug Testing and Anal"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022\u20101759(01)00355\u20106"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102020\u20100074"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio\u20102021\u20100027"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000643"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3260","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.3260","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:49:43Z","timestamp":1760384983000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/dta.3260"],"URL":"https:\/\/doi.org\/10.1002\/dta.3260","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"2022-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}